Following arrival at the laboratory, study procedures were explained to the participants and written informed consent was obtained. The ActiGraph GT3X+ and GENEActiv accelerometers were then attached to both the hip (right side) and wrist (non-dominant). Consequently, a total of 4 devices were worn by each participant (1 ActiGraph GT3X+ on the hip and wrist; and 1 GENEActiv on the hip and wrist) whilst they performed 16 different activities (4 lying positions, 7 sitting postures and 5 upright activities) in a sequential order for 5 minutes each under laboratory-conditions. The start and end time of each activity was observed (using a clock on a computer) and recorded onto a log sheet. A 30 second break was allocated between each activity. Table 1 summarises the sedentary behaviours and light-intensity physical activities undertaken by the participants.
>
Chemicals & Drugs
>
Amino Acid
>
HIP1 protein, human
HIP1 protein, human
The HIP1 protein, also known as Huntingtin-interacting protein 1, is a key component of the clathrin-mediated endocytosis pathway.
It plays a crucial role in the internalization of cell surface receptors and the trafficking of endocytic vesicles.
HIP1 has been implicated in various cellular processes, including synaptic function, neurodegeneration, and cancer development.
Researchers can leverage PubCompare.ai's AI-driven platform to efficiently explore the HIP1 protein, locate the best research protocols, and enhance the reproducibility of their studies, optimizing their HIP1 protein research workflow.
It plays a crucial role in the internalization of cell surface receptors and the trafficking of endocytic vesicles.
HIP1 has been implicated in various cellular processes, including synaptic function, neurodegeneration, and cancer development.
Researchers can leverage PubCompare.ai's AI-driven platform to efficiently explore the HIP1 protein, locate the best research protocols, and enhance the reproducibility of their studies, optimizing their HIP1 protein research workflow.
Most cited protocols related to «HIP1 protein, human»
Actigraphy
HIP1 protein, human
Light
Medical Devices
Wrist
Body Weight
Bone Cements
Bones
Diagnosis
Diaphyses
Femur
Fracture, Bone
HIP1 protein, human
Lumbar Region
Paraspinal Muscles
Tissues
Trochanter
Vertebra
Vertebral Column
Woman
X-Ray Computed Tomography
UCLA score distribution and responsiveness (validity of change scores) were evaluated at Lillebaelt Hospital—Vejle, Region of Southern Denmark. As part of the normal clinical routine, through 5 months (inclusion March–July 2018), hip OA patients scheduled for HA and knee OA patients scheduled for total or medial unicompartmental KA completed electronic PROM questionnaires (forcing patients to choose only one answer option) before and 1 year after surgery (Procordo Software, Copenhagen). Patients who had revision surgery during year 1 were excluded. Paper versions were available for patients with no email address. Non-responders were reminded by mail and, if necessary, by phone. The PROM questionnaires included UCLA, and the well-established Oxford Hip or Knee Score (OHS, OKS) (Dawson et al. 1996 , 1998 , Murray et al. 2007 (link), Hossain et al. 2015 ), the generic EQ-5D-5L and EQ-5D VAS (Jin et al. 2019 (link)), and an overall patient satisfaction question (“How satisfied are you with your hip/knee 1 year after surgery?”, 5 answer options, 1 neutral).
Responsiveness was evaluated by use of the construct approach (de Vet et al. 2011 ), i.e., correlation of UCLA change with other PROM change scores and overall satisfaction. We expected only fair to moderate correlations (Naal et al. 2009 (link)) because (1) generic and joint-specific PROMs evaluate factors other than physical activity, (2) joint replacement may improve the ability to be physically active without changing the patients’ habits (because of, e.g., lack of motivation), and (3) perception of change may be influenced by preoperative expectations.
A mean increase of 1–3 UCLA levels 1 year after surgery was expected (SooHoo et al. 2015 , Ghomrawi et al. 2017 (link), Scott et al. 2017 (link)), as was a 2-fold increase in the proportion of patients with UCLA score ≥ 6 (Scott et al. 2017 (link)). We also calculated the effect size, a traditional distribution-based measure to quantify responsiveness (Angst 2011 (link)).
Responsiveness was evaluated by use of the construct approach (de Vet et al. 2011 ), i.e., correlation of UCLA change with other PROM change scores and overall satisfaction. We expected only fair to moderate correlations (Naal et al. 2009 (link)) because (1) generic and joint-specific PROMs evaluate factors other than physical activity, (2) joint replacement may improve the ability to be physically active without changing the patients’ habits (because of, e.g., lack of motivation), and (3) perception of change may be influenced by preoperative expectations.
A mean increase of 1–3 UCLA levels 1 year after surgery was expected (SooHoo et al. 2015 , Ghomrawi et al. 2017 (link), Scott et al. 2017 (link)), as was a 2-fold increase in the proportion of patients with UCLA score ≥ 6 (Scott et al. 2017 (link)). We also calculated the effect size, a traditional distribution-based measure to quantify responsiveness (Angst 2011 (link)).
Anxiety
Arthroplasty, Replacement
Generic Drugs
HIP1 protein, human
Joints
Knee
Motivation
Operative Surgical Procedures
Osteoarthritis Of Hip
Patients
Repeat Surgery
Satisfaction
The weight-bearing FLX before and after surgery (the preoperative ones were taken within 1 month before surgery and the postoperative ones 3 days after surgery) of the patients were collected via the picture archiving and communication system (PACS) and imported into Autodesk AutoCAD 2019 for measurement of preoperative hip-knee-ankle (HKA) angles and postoperative frontal femoral component angle (FFC), lateral femoral component angle (LFC) [30 (link)], frontal tibial component angle (FTC), lateral tibial component angle (LTC) [31 , 32 (link)], and HKA angles (Fig. 3 ). Three surgeons specializing in TKA performed blind measurement twice; in order to ensure that the raters had sufficient forgetting time, each was required to measure at an interval for more than 2 weeks [33 (link), 34 (link)]. For HKA, the varus was defined as negative and the valgus positive; for LTC, the retroversion was positive and the anteversion negative. Values exceeding the target value by 3° were recorded as outliers, and the percentage of outliers was calculated. Patients with varus knee preoperatively who had HKA valgus greater than 1° after surgery and patients with valgus knee preoperatively who had HKA varus greater than 1° after surgery were recorded as overcorrected, and the percentage of overcorrection was calculated.
Medical records such as the operation time, tourniquet time, hospital stay, intraoperative bleeding, incidence of postoperative complications, hemoglobin value 1 day before the operation, 1 day after the operation, and 3 days after operation were collected via the electronic medical record management system. And visual analog scale (VAS) score and New Knee Society Score (NEW-KSS) [35 (link)] before operation and 1, 6, and 12 months after operation were recorded.
This study has been approved by the local Ethics Committee (No. KY2019123).
Medical records such as the operation time, tourniquet time, hospital stay, intraoperative bleeding, incidence of postoperative complications, hemoglobin value 1 day before the operation, 1 day after the operation, and 3 days after operation were collected via the electronic medical record management system. And visual analog scale (VAS) score and New Knee Society Score (NEW-KSS) [35 (link)] before operation and 1, 6, and 12 months after operation were recorded.
This study has been approved by the local Ethics Committee (No. KY2019123).
Ankle
Femur
Hemoglobin
HIP1 protein, human
Knee
Patients
Postoperative Complications
Regional Ethics Committees
Surgeons
Surgery, Day
Tibia
Tourniquets
Valga, Coxa
Visual Analog Pain Scale
Visually Impaired Persons
The expression of P-selectin and the binding of the monoclonal antibody PAC-1 to activated glycoprotein IIb/IIIa (GPIIb/IIIa) were determined in citrate-anticoagulated blood, as previously published [11 (link)]. In brief, whole blood was diluted in phosphate-buffered saline to obtain 20x103/μL platelets in 20μl, and incubated for 10 minutes without agonists, and after in vitro exposure to suboptimal concentrations of ADP (final concentration 1μM; Dynabyte, Munich, Germany) or AA (final concentration 80 μM; Diamed, Cressier, Switzerland), each 10 μL. The platelet population was identified by staining with anti-CD42b (5 μL of clone HIP1, allophycocyanin labelled, final dilution 1:9; Becton Dickinson (BD), San Jose, CA, USA), and the expression of P-selectin and activated GPIIb/IIIa were determined by the binding of the monoclonal antibodies PAC-1-fluorescein (5 μL, final dilution 1:9; BD) and anti-CD62p-phycoerythrin (5 μL of clone CLB-Thromb6, final dilution 1:9; Immunotech, Beckman Coulter, Fullerton, CA, USA), respectively. Isotype-matched control antibodies were used in separate vials for the determination of non-specific binding. After 15 minutes of incubation in the dark, the reaction was stopped by adding 500 μL PBS and samples were acquired immediately on a FACS Calibur flow cytometer (BD) with excitation by an argon laser at 488 nm and a red diode laser at 635 nm at a rate of 200–600 events per second. FITC and PE labelled beads were used to compensate manually for the FITC signal into the PE channel and vice versa. Platelets were gated in a side scatter versus FL4 dot plot. A total of 10.000 events were acquired within this gate. Positive analysis regions for P-selectin and activated GPIIb/IIIa, respectively, were set with appropriate nonspecific controls. The gated events were further analyzed in histograms for FL-1 and FL-2 for PAC-1 and P-selectin, respectively, using the CellQuest Pro software (BD). Agonists’-induced P-selectin and activated GPIIb/IIIa were calculated as fold change of mean fluorescence intensities (MFI) after the addition of ADP or AA according to the following formula:
Agonists´-induced P-selectin or GPIIb/IIIa = P-selectin or GPIIb/IIIa MFI after the addition of ADP or AA/ P-selectin or GPIIb/IIIa MFI without agonist
Standard BD calibrite beads were used for daily calibration of the cytometer.
Agonists´-induced P-selectin or GPIIb/IIIa = P-selectin or GPIIb/IIIa MFI after the addition of ADP or AA/ P-selectin or GPIIb/IIIa MFI without agonist
Standard BD calibrite beads were used for daily calibration of the cytometer.
agonists
allophycocyanin
Antibodies
Argon Ion Lasers
BLOOD
Blood Platelets
Citrates
Clone Cells
Fluorescein
Fluorescein-5-isothiocyanate
Fluorescence
HIP1 protein, human
Immunoglobulin Isotypes
Lasers, Semiconductor
Monoclonal Antibodies
Phosphates
Phycoerythrin
Platelet Glycoprotein GPIIb-IIIa Complex
Saline Solution
SELP protein, human
Technique, Dilution
Most recents protocols related to «HIP1 protein, human»
BMD was measured by DXA (Lunar Expert-1313; Lunar Corp, Madison, WI, USA), and BMD T-score was calculated as the difference between the BMD of an individual and that of the reference population divided by the standard deviation (SD) of the reference population. This study evaluated the total hip BMD T-score as the primary outcome because the risk of hip fracture increased significantly in T2DM (25 (link)–27 (link)), and T2DM patients with hip fracture suffered high post-hip fracture mortality (28 (link)). According to the WHO diagnostic criteria, osteoporosis is defined as a BMD T-score lower than or equal to -2.5 SD, low bone mass (osteopenia) as a BMD T-score between -2.5 and -1 SD, and normal BMD as T-score equal to or greater than -1 SD (29 (link)). Therefore, the subjects were divided into two groups: the normal BMD group with total hip BMD T-score ≥-1 and the low BMD group, including low bone mass (osteopenia) and osteoporosis, with total hip BMD T-Score < -1.
As-A 2
Bone Density
Diagnosis
HIP1 protein, human
Hip Fractures
Osteopenia
Osteoporosis
Patients
Silver
The protocol for this study received institutional review board approval, and all
participants provided informed consent. We conducted a retrospective analysis of 24
symptomatic patients (37 hips) with anterior FAI who were seen at our outpatient
clinic between January 2014 and December 2016. The patients were part of a previous study.24
Inclusion criteria were FV <5° on CT scan (termed decreased
FV) and the absence of hip dysplasia. Exclusion criteria were a lateral
center-edge angle49 (link)
<22° or an acetabular index53 (link)
>14° and Tönnis grade ≥1 osteoarthritis.52
All patients had undergone standardized anteroposterior and lateral
radiographs as well as CT scans including the entire pelvis and the knee joint
(distal femoral condyles)34 (link),35 (link)
according to a previously described protocol.24 ,42
At the time of imaging, all patients were symptomatic and had anterior groin
pain, a positive FADIR test result (performed at 90° of flexion and forced IR), and
decreased IR during clinical examination. Some patients also reported hip pain at
maximal flexion.
Considerable differences for FV measurement exist.42
In the current study, we measured FV on standardized pelvic CT scans using
the method of Murphy et al.30 (link)
This method has small interobserver variability.26 ,42
The hips with decreased FV were categorized into those with absolute femoral
retroversion (FV <0°) and those with decreased combined version (McKibbin index22 (link)
<20°). Definitions of the terms used in this study are listed inTable 1 .
Of the 37 hips with decreased FV, 16 (43%) had cam deformity, 7 (19%) had pincer-type
deformity, 6 (16%) had combined cam and pincer deformity (mixed-type FAI), and 8
(22%) had neither cam- nor pincer-type morphology. There were 13 hips with absolute
femoral retroversion (Figure
1 ) and 29 hips with decreased combined version (Table 2 ); the 2 subgroups could overlap,
and some of the hips were part of both groups. Most of the 24 study patients were
male (62%), with a mean ± SD age of 28 ± 9 years and FV of 1° ± 4°.
In addition to the study groups, we included a control group of 26 unaffected hips
from the contralateral side of 146 patients who had undergone THA. The mean age of
the control group was 54 ± 11 years. Exclusion criteria for the control group were
as follows: THA or total knee arthroplasty (n = 10), pain (n = 4), previous hip
surgery (n = 3), Tönnis grade ≥1 osteoarthritis52
(n = 40), lateral center-edge angle <25° (n = 24), pistol grip deformity48 (link)
(n = 13), coxa profunda (n = 13), coxa vara or valga (n = 1), acetabular retroversion40 (link),51 (link)
(n = 4), protrusio acetabuli (n = 2), alpha angle >50° (n = 4), and
femoral retroversion (n = 2).
participants provided informed consent. We conducted a retrospective analysis of 24
symptomatic patients (37 hips) with anterior FAI who were seen at our outpatient
clinic between January 2014 and December 2016. The patients were part of a previous study.24
Inclusion criteria were FV <5° on CT scan (termed decreased
FV) and the absence of hip dysplasia. Exclusion criteria were a lateral
center-edge angle49 (link)
<22° or an acetabular index53 (link)
>14° and Tönnis grade ≥1 osteoarthritis.52
All patients had undergone standardized anteroposterior and lateral
radiographs as well as CT scans including the entire pelvis and the knee joint
(distal femoral condyles)34 (link),35 (link)
according to a previously described protocol.24 ,42
At the time of imaging, all patients were symptomatic and had anterior groin
pain, a positive FADIR test result (performed at 90° of flexion and forced IR), and
decreased IR during clinical examination. Some patients also reported hip pain at
maximal flexion.
Considerable differences for FV measurement exist.42
In the current study, we measured FV on standardized pelvic CT scans using
the method of Murphy et al.30 (link)
This method has small interobserver variability.26 ,42
The hips with decreased FV were categorized into those with absolute femoral
retroversion (FV <0°) and those with decreased combined version (McKibbin index22 (link)
<20°). Definitions of the terms used in this study are listed in
Of the 37 hips with decreased FV, 16 (43%) had cam deformity, 7 (19%) had pincer-type
deformity, 6 (16%) had combined cam and pincer deformity (mixed-type FAI), and 8
(22%) had neither cam- nor pincer-type morphology. There were 13 hips with absolute
femoral retroversion (
1
and some of the hips were part of both groups. Most of the 24 study patients were
male (62%), with a mean ± SD age of 28 ± 9 years and FV of 1° ± 4°.
In addition to the study groups, we included a control group of 26 unaffected hips
from the contralateral side of 146 patients who had undergone THA. The mean age of
the control group was 54 ± 11 years. Exclusion criteria for the control group were
as follows: THA or total knee arthroplasty (n = 10), pain (n = 4), previous hip
surgery (n = 3), Tönnis grade ≥1 osteoarthritis52
(n = 40), lateral center-edge angle <25° (n = 24), pistol grip deformity48 (link)
(n = 13), coxa profunda (n = 13), coxa vara or valga (n = 1), acetabular retroversion40 (link),51 (link)
(n = 4), protrusio acetabuli (n = 2), alpha angle >50° (n = 4), and
femoral retroversion (n = 2).
Acetabulum
Condyle
Congenital Abnormality
Coxa
Degenerative Arthritides
Ethics Committees, Research
Femur
Grasp
HIP1 protein, human
Hip Dysplasia
Knee Joint
Knee Replacement Arthroplasty
Pain
Patients
Pelvis
Physical Examination
Varas, Coxa
Vision
X-Ray Computed Tomography
We conducted a cross-sectional cohort study where US and MARS-MRI were compared including patients operated at 2 hospitals. The cohort consisted of patients with hip resurfacing arthroplasty (HRA) (ASR, Depuy) and MoM THA (M2a-Magnum, Biomet). In 2011, all patients with these 2 types of hip arthroplasty and operated at the 2 centers during 2005–2010 were invited. Further, we had a matched control group of patients with MoP THA from those 2 centers from the same period, matched with the first 50 from HRA patients at 1 of the centers. The control group was matched on sex, age, and year of surgery. The cohort was part of another study into the prevalence of MARS-MRI detected PT between HRA, MoM, and MoP THA. In total, 205 patients with 121 HRA, 34 MoM, and 50 MoP THA were included in the cohort (Figure 1 ).![]()
Flowchart of inclusion and exclusion of patients. HRA: Hip resurfacing arthroplasty. MoM: Metal-on-metal. THA: Total hip arthroplasty. MoP: Metal-on-polyethylene.
Arthroplasty
Biomet
HIP1 protein, human
Metals
Operative Surgical Procedures
Patients
Polyethylene, High-Density
SLC7A7 protein, human
Total Hip Arthroplasty
Motion capture was performed in the Gait Laboratory of the Department of Human Anatomy of Southern Medical University. Reflective markers were attached at the positions of the subject’s body surface landmarks. The 3-D motion capture system (Qualisys, Gothenburg, Sweden) consisting of 12 infrared cameras (Miqus M1, Qualisys, Sweden) and 1 video camera (Miqus Video, Qualisys, Sweden) was used to obtain the movement trajectories of body surface landmarks during walking at a frequency of 100 Hz, and three force plates (type 9260AA6, 500 mm × 600 mm; Kistler, Switzerland) aligned with the walkway, were used to measure the ground reaction forces (GRFs) at a frequency of 100 Hz. Heel strikes and toe-offs were defined using a GRF threshold of 10 N, and the gait cycle was defined from heel-strike to heel-strike.
The movements of 18 healthy hips (9 left hips, 9 right hip) of 9 healthy people were collected, and the movements of the 12 affected hips (5 left hips, 7 right hips) of 9 patients were collected. Each hip was measured separately for two movement states, including normal and long stride walking. For normal walking, the subjects walked along the force plates at a self-selected comfortable speed (mean stride, 1.17 ± 0.04 m for healthy hip, 1.18 ± 0.06 m for affected hips). For long stride walking, the subjects were asked to walk with the maximum stride as they can (mean stride, 1.66 ± 0.24 m for healthy hips, 1.63 ± 0.26 m for affected hips). The walking speed of two movement states, including normal and long stride walking was measured for healthy hips (mean, 1.02 ± 0.08 m/s for normal walking, 1.05 ± 0.14 m/s for long stride walking) and affected hips (mean, 0.96 ± 0.10 m/s for normal walking, 1.15 ± 0.14 m/s for long stride walking). The subjects performed a 5-min warm-up protocol of comfortable walking before the formal test.
The movements of 18 healthy hips (9 left hips, 9 right hip) of 9 healthy people were collected, and the movements of the 12 affected hips (5 left hips, 7 right hips) of 9 patients were collected. Each hip was measured separately for two movement states, including normal and long stride walking. For normal walking, the subjects walked along the force plates at a self-selected comfortable speed (mean stride, 1.17 ± 0.04 m for healthy hip, 1.18 ± 0.06 m for affected hips). For long stride walking, the subjects were asked to walk with the maximum stride as they can (mean stride, 1.66 ± 0.24 m for healthy hips, 1.63 ± 0.26 m for affected hips). The walking speed of two movement states, including normal and long stride walking was measured for healthy hips (mean, 1.02 ± 0.08 m/s for normal walking, 1.05 ± 0.14 m/s for long stride walking) and affected hips (mean, 0.96 ± 0.10 m/s for normal walking, 1.15 ± 0.14 m/s for long stride walking). The subjects performed a 5-min warm-up protocol of comfortable walking before the formal test.
Coxa
Heel
HIP1 protein, human
Homo sapiens
Movement
Patients
In the second phase, we enrolled only fragility hip fracture patients who did not receive anti-osteoporosis medication 1 year after their hip fracture treatment. We excluded patients with severe cognitive or neurological impairments that might affect their ability to respond to a questionnaire. Additionally, patients were excluded if they had chronic kidney disease stage 5 (estimated glomerular filtration rate < 15 mL/min/1.73m2) or end-stage renal disease (ESRD). Both conditions are contraindicated for most anti-osteoporosis medications, including our first-line anti-osteoporosis agent, oral bisphosphonate.
Each patient (or a relative/caregiver) provided informed consent in writing or by telephone to participate in this second study phase. All patient information was kept confidential. The study design and reporting format followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) principles. All eligible patients who met the inclusion criteria of the cross-sectional phase were interviewed using a no-treatment questionnaire. A research assistant interviewed individual patients either face-to-face or by telephone.
Each patient (or a relative/caregiver) provided informed consent in writing or by telephone to participate in this second study phase. All patient information was kept confidential. The study design and reporting format followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) principles. All eligible patients who met the inclusion criteria of the cross-sectional phase were interviewed using a no-treatment questionnaire. A research assistant interviewed individual patients either face-to-face or by telephone.
Chronic Kidney Diseases
Cognition
Diphosphonates
Face
Glomerular Filtration Rate
HIP1 protein, human
Hip Fractures
Kidney Failure, Chronic
Osteoporosis
Osteoporotic Fractures
Patients
Pharmaceutical Preparations
Top products related to «HIP1 protein, human»
Sourced in United States, United Kingdom, Japan, Germany, Belgium, Denmark
The Lunar iDXA is a dual-energy X-ray absorptiometry (DXA) system used for the measurement of bone mineral density and body composition. It provides accurate and precise assessments of bone, lean, and fat mass.
Sourced in United States, United Kingdom, New Zealand
The QDR 4500A is a dual-energy X-ray absorptiometry (DXA) system designed for bone density measurements. It is a diagnostic medical device used to assess bone mineral density (BMD) and evaluate the risk of osteoporosis.
Sourced in United States, United Kingdom, Morocco
The QDR 4500 is a dual-energy X-ray absorptiometry (DXA) system designed for bone mineral density (BMD) measurements. It is a diagnostic device used to assess bone health and detect conditions such as osteoporosis.
Sourced in United States, Germany, United Kingdom, Belgium, China, Australia, France, Japan, Italy, Spain, Switzerland, Canada, Uruguay, Netherlands, Czechia, Jersey, Brazil, Denmark, Singapore, Austria, India, Panama
The FACSCanto II is a flow cytometer instrument designed for multi-parameter analysis of single cells. It features a solid-state diode laser and up to four fluorescence detectors for simultaneous measurement of multiple cellular parameters.
Sourced in United States, Switzerland, Germany, China, United Kingdom, France, Canada, Japan, Italy, Australia, Austria, Sweden, Spain, Cameroon, India, Macao, Belgium, Israel
Protease inhibitor cocktail is a laboratory reagent used to inhibit the activity of proteases, which are enzymes that break down proteins. It is commonly used in protein extraction and purification procedures to prevent protein degradation.
Sourced in United States
Prism 7.0a is a data analysis and graph-making software from GraphPad. It allows users to analyze, visualize, and present scientific data. The software provides a range of tools for data management, statistical analysis, and customizable graph creation.
Sourced in United States, Germany, United Kingdom, Italy, France, China, Macao, Poland, Switzerland, Spain, Sao Tome and Principe, Japan, Brazil, Canada, Australia, Belgium, Austria, Netherlands, Israel, India, Sweden, Denmark, Ireland, Czechia, Norway, Gabon, Argentina, Portugal, Hungary, Holy See (Vatican City State), Mexico, Ukraine, Slovakia
Streptomycin is a laboratory product manufactured by Merck Group. It is an antibiotic used in research applications.
Sourced in United States, United Kingdom, Germany, Belgium, Japan, Morocco
The Lunar Prodigy is a bone densitometry system designed for the assessment of bone mineral density (BMD) and body composition. It utilizes dual-energy X-ray absorptiometry (DXA) technology to provide accurate and reproducible measurements.
Sourced in United States, United Kingdom, Germany, Belgium, Canada, France, Italy, China, Switzerland, Australia, Japan, Brazil, Singapore
The BD Accuri C6 flow cytometer is a compact, automated instrument designed for cell analysis. It uses flow cytometry technology to precisely count and characterize cells in a sample. The BD Accuri C6 measures various parameters, such as cell size and granularity, to provide detailed information about the sample.
Sourced in Germany, United States, United Kingdom, Netherlands, China, Canada, Spain, Japan, Italy, France, Australia, Norway, Denmark, Sweden, Belgium
The MiRNeasy Mini Kit is a laboratory instrument designed for the extraction and purification of microRNA (miRNA) and other small RNA molecules from a variety of sample types, including cells, tissues, and body fluids. The kit utilizes a silica-membrane-based technology to facilitate the efficient isolation of high-quality miRNA and small RNA.
More about "HIP1 protein, human"
The HIP1 (Huntingtin-interacting protein 1) is a crucial component of the clathrin-mediated endocytosis pathway, playing a vital role in the internalization of cell surface receptors and the trafficking of endocytic vesicles.
This multifunctional protein has been implicated in various cellular processes, including synaptic function, neurodegeneration, and cancer development.
Researchers can leverage PubCompare.ai's AI-driven platform to efficiently explore the HIP1 protein and its associated topics.
This includes locating the best research protocols from literature, preprints, and patents, as well as enhancing the reproducibility of their studies through smart comparison tools.
The HIP1 protein, also known as the Huntingtin-interacting protein 1, is involved in a range of cellular processes.
It interacts with the Huntingtin protein, which is associated with Huntington's disease, a neurodegenerative disorder.
Additionally, HIP1 plays a crucial role in clathrin-mediated endocytosis, a process that internalizes cell surface receptors and traffics endocytic vesicles.
Exploring the HIP1 protein can provide valuable insights into synaptic function, as it is involved in the regulation of synaptic transmission and plasticity.
Researchers may also investigate the role of HIP1 in neurodegeneration, as disruptions in its function have been linked to various neurodegenerative diseases, such as Alzheimer's and Parkinson's.
Furthermore, the HIP1 protein has been implicated in cancer development, as it interacts with several signaling pathways and cellular processes that are dysregulated in cancer.
Studying the HIP1 protein can shed light on the mechanisms underlying cancer progression and potentially inform the development of targeted therapies.
To optimize their HIP1 protein research workflow, researchers can utilize PubCompare.ai's AI-driven platform.
This tool can help identify the best research protocols from a vast pool of literature, preprints, and patents, ensuring that their studies are based on the most up-to-date and reliable information.
Additionally, the platform's smart comparison tools can enhance the reproducibility of their experiments, improving the overall quality and impact of their HIP1 protein research.
In conclusion, the HIP1 protein is a fascinating and multifaceted subject of study, with implications in various areas of biology and medicine.
By leveraging PubCompare.ai's AI-driven platform, researchers can efficiently explore the HIP1 protein, locate the best research protocols, and enhance the reproducibility of their studies, leading to advancements in our understanding of this important cellular component.
This multifunctional protein has been implicated in various cellular processes, including synaptic function, neurodegeneration, and cancer development.
Researchers can leverage PubCompare.ai's AI-driven platform to efficiently explore the HIP1 protein and its associated topics.
This includes locating the best research protocols from literature, preprints, and patents, as well as enhancing the reproducibility of their studies through smart comparison tools.
The HIP1 protein, also known as the Huntingtin-interacting protein 1, is involved in a range of cellular processes.
It interacts with the Huntingtin protein, which is associated with Huntington's disease, a neurodegenerative disorder.
Additionally, HIP1 plays a crucial role in clathrin-mediated endocytosis, a process that internalizes cell surface receptors and traffics endocytic vesicles.
Exploring the HIP1 protein can provide valuable insights into synaptic function, as it is involved in the regulation of synaptic transmission and plasticity.
Researchers may also investigate the role of HIP1 in neurodegeneration, as disruptions in its function have been linked to various neurodegenerative diseases, such as Alzheimer's and Parkinson's.
Furthermore, the HIP1 protein has been implicated in cancer development, as it interacts with several signaling pathways and cellular processes that are dysregulated in cancer.
Studying the HIP1 protein can shed light on the mechanisms underlying cancer progression and potentially inform the development of targeted therapies.
To optimize their HIP1 protein research workflow, researchers can utilize PubCompare.ai's AI-driven platform.
This tool can help identify the best research protocols from a vast pool of literature, preprints, and patents, ensuring that their studies are based on the most up-to-date and reliable information.
Additionally, the platform's smart comparison tools can enhance the reproducibility of their experiments, improving the overall quality and impact of their HIP1 protein research.
In conclusion, the HIP1 protein is a fascinating and multifaceted subject of study, with implications in various areas of biology and medicine.
By leveraging PubCompare.ai's AI-driven platform, researchers can efficiently explore the HIP1 protein, locate the best research protocols, and enhance the reproducibility of their studies, leading to advancements in our understanding of this important cellular component.